UCB SA

A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.

Pharma & Biotech

BIMZELX beat AbbVie’s US$5.8bn-a-quarter SKYRIZI on joint response. Why UCB still cannot claim broad superiority

by Pallavi Madhiraju
November 10, 2026
0 Comments

BIMZELX sustained higher ACR50 than SKYRIZI at Week 24, but UCB’s statistical hierarchy limits broader superiority claims.

Read More